Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600383 | 1.00 | TLR2 (0.54) | TLR2MDM2KMT2AHDAC4MEF2D | |
| SCHEMBL14596250 | 0.97 | TLR2 (0.57) | TLR2MDM2KMT2AHDAC4MEF2D | |
| SCHEMBL14110980 | 0.97 | TLR2 (0.57) | TLR2MDM2KMT2AHDAC4MEF2D | |
| SCHEMBL4599971 | 0.94 | TLR2 (0.49) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL4885335 | 0.94 | TLR2 (0.49) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL4598817 | 0.90 | KMT2A (0.49) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL4598821 | 0.90 | KMT2A (0.49) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL14111048 | 0.89 | TLR2 (0.59) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL14596249 | 0.89 | TLR2 (0.59) | TLR2MDM2KMT2AEPHX2 | |
| SCHEMBL4419945 | 0.85 | CTSK (0.50) | MDM2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | TLR2 2757/4885MDM2 3730/4885KMT2A 3406/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | TLR2 4726/4885MDM2 2451/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.